Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer

Table 2 Univariate analysis for the relationship between clinical characteristics, rpS6, p-rpS6 expressions and survival time in different groups

Factors		All patients			Patients in I stage			Patients in II+III+IV stage
Factors		HR	95 % CI	P	HR	95 % CI	P	HR	95 % CI	P
Gender	Male vs Female	1.288	0.961–1.726	0.091	2.021	0.900–4.539	0.088	1.110	0.810–1.522	0.516
Age/years	< 60 vs ≥ 60	1.009	0.792–1.286	0.943	1.153	0.639–2.083	0.635	0.906	0.692–1.185	0.469
Histological type	ADC vs SCC vs others	0.957	0.801–1.144	0.630	0.646	0.397–1.052	0.079	0.975	0.808–1.177	0.793
Histological differentiation	Poor vs moderate/well	1.369	1.078–1.174	0.010*	1.604	0.882–2.915	0.122	1.058	0.815–1.374	0.672
Tumor size	T3+T4 vs T1+T2	2.154	1.680–2.762	< 0.001*	-	-	-	1.195	0.904–1.508	0.210
Lymph node invasion	N1+N2+N3 vs N0	2.121	1.636–2.749	< 0.001*	-	-	-	0.882	0.650–1.197	0.420
Distant metastasis	M1 vs M0	1.835	1.181–2.851	0.007*	-	-	-	1.401	0.898–2.185	0.137
Stage	II+III+IV vs I	4.143	2.945–5.831	< 0.001*	-	-	-	-	-	-
t-rpS6	P vs N	1.206	0.882–1.647	0.241	0.791	0.407–1.536	0.489	1.430	0.989–2.069	0.580
p-rpS6	P vs N	2.666	2.056–3.456	< 0.001*	5.916	2.920–11.984	< 0.001*	1.560	1.165–2.089	0.003*
p-rpS6/t-rpS6	≥ 0.67 vs < 0.67	5.963	4.437–8.016	< 0.001*	12.304	6.046–25.042	< 0.001*	3.654	2.641–5.056	< 0.001*

HR hazard ratio; CI confidence interval; t-rpS6 total rpS6; p-rpS6 phosphorylation of rpS6; ADC adenocarcinoma; SCC squamous cell carcinoma; P positive expression; N negative expression
-: No calculation was carried out because of the absence of dependent factors. For example, tumor sizes in I stage patients were always in T1 or T2, indicating an impossible comparison with T3 and T4 ones. Similarly, patients in I stage were always without any lymph node invasion or distant metastasis
*: P < 0.05

ISSN: 1756-9966